David Westenberg, an analyst from Piper Sandler, has initiated a new Buy rating on BillionToOne, Inc. Class A (BLLN).
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
David Westenberg’s rating is based on BillionToOne’s innovative platform that targets molecules at single count levels, which has enabled the company to launch a competitive cfDNA test focusing on fetal DNA. This advancement is expected to drive a significant revenue growth in the reproductive health sector, with a projected 25%+ CAGR. The company’s first-mover advantage in this domain positions it well to capture a substantial share of the market as it shifts towards this new testing paradigm.
Furthermore, BillionToOne’s technology is poised to tap into the expansive liquid biopsy market, which is estimated to be over $100 billion and growing. The potential for therapy selection and monitoring in oncology, where detecting actionable mutations can be transformative, adds to the company’s growth prospects. As the frequency of genomic profiling tests increases, BillionToOne is well-positioned to benefit from the evolving treatment paradigms in oncology.
Based on the recent corporate insider activity of 28 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BLLN in relation to earlier this year.